테스토스테론 보충 요법 시장 규모, 점유율 및 동향 분석 보고서 - 최종 사용자별, 제품 유형별, 활성 및 지역별 전망 및 예측(2024-2031년)
Global Testosterone Replacement Therapy Market Size, Share & Trends Analysis Report By End User (Clinics, and Hospital), By Product Type (Injectables, Topical, and Others), By Active, By Regional Outlook and Forecast, 2024 - 2031
상품코드:1473123
리서치사:KBV Research
발행일:2024년 04월
페이지 정보:영문 267 Pages
라이선스 & 가격 (부가세 별도)
한글목차
테스토스테론 보충 요법(TRT) 시장 규모는 예측 기간 동안 4.1%의 연평균 복합 성장률(CAGR)로 성장하여 2031년까지 25억 달러에 달할 것으로 예상됩니다.
또한, 의료비가 증가하면 예방 의료, 진단 검사, 전문 치료 등 의료 서비스를 받을 수 있는 사람이 늘어납니다. 접근성이 확대되면 성선기능저하증과 같은 증상에 대해 의사의 조언과 치료를 받을 수 있는 남성이 늘어나면서 TRT에 대한 수요가 증가합니다. 의료비 증가에 따라 진단 기술, 검진 프로그램, 의료 인프라에 대한 투자도 증가합니다. 결론적으로, 의료 부문의 지출 증가가 시장 성장을 주도하고 있습니다.
그러나 TRT는 특히 장기 치료의 경우 비용이 많이 들 수 있습니다. TRT 비용에는 테스토스테론 약값뿐만 아니라 의사 진료, 임상시험, 모니터링 및 후속 진료 예약과 관련된 비용도 포함됩니다. 이 없는 사람들에게는 치료를 시작하거나 지속할 수 있는 능력을 제한하는 큰 장애물이 될 수 있습니다. 결론적으로, 테스토스테론 보충 요법의 높은 비용은 시장 성장을 저해하고 있습니다.
시장은 원자재, 제조, 유통에 있어 복잡한 세계 공급망에 의존하고 있습니다. 공장 폐쇄, 운송 제한, 노동력 부족 등 공급망의 혼란으로 인해 제품 생산이 지연되고 일부 지역에서는 TRT 의약품이 부족해졌습니다. 따라서 코로나19 팬데믹은 시장 성장에 부정적인 영향을 미쳤습니다.
목차
제1장 시장 범위와 조사 방법
시장의 정의
목적
시장 범위
세분화
조사 방법
제2장 시장 요람
제3장 시장 개요
서론
개요
시장 구성과 시나리오
시장에 영향을 미치는 주요 요인
시장 성장 촉진요인
시장 성장 억제요인
시장 기회
시장이 해결해야 할 과제
Porter의 Five Forces 분석
제4장 세계 시장 : 최종사용자별
세계의 클리닉 시장 : 지역별
세계의 병원 시장 : 지역별
제5장 세계 시장 : 제품 유형별
세계의 주사 시장 : 지역별
세계의 국소 시장 : 지역별
세계의 기타 시장 : 지역별
제6장 세계 시장 : 유효 성분별
세계의 테스트스테론 사이피오네이트 시장 : 지역별
세계의 테스트스테론 언데카네이트 시장 : 지역별
세계의 테스트스테론 에난테이트 시장 : 지역별
세계의 테스토스테론 시장 : 지역별
세계의 기타 시장 : 지역별
제7장 세계 시장 : 지역별
북미
북미 시장 : 국가별
미국
캐나다
멕시코
기타 북미
유럽
유럽 시장 : 국가별
독일
영국
프랑스
러시아
스페인
이탈리아
기타 유럽
아시아태평양
아시아태평양 시장 : 국가별
중국
일본
인도
한국
싱가포르
호주
기타 아시아태평양
라틴아메리카/중동 및 아프리카
라틴아메리카/중동 및 아프리카 시장 : 국가별
브라질
아르헨티나
아랍에미리트(UAE)
사우디아라비아
남아프리카공화국
나이지리아
기타 라틴아메리카/중동 및 아프리카
제8장 기업 개요
Endo International PLC
AbbVie, Inc
Pfizer, Inc
Eli Lilly And Company
Teva Pharmaceutical Industries Ltd
Amneal Pharmaceuticals, Inc
Ferring Holdings SA
Marius Pharmaceuticals LLC
Besins Healthcare Monaco SA.M
Acrux Limited
제9장 테스토스테론 보충 요법 시장을 위한 성공 필수 조건
LSH
영문 목차
영문목차
The Global Testosterone Replacement Therapy Market size is expected to reach $2.5 billion by 2031, rising at a market growth of 4.1% CAGR during the forecast period.
Testosterone enanthate has been widely used and studied for TRT, demonstrating consistent effectiveness in restoring testosterone levels to within the normal physiological range and improving symptoms of hypogonadism. Consequently, the testosterone enanthate segment would generate approximately 19.3% revenue share of the market by 2031. Clinical trials and real-world experience have shown that testosterone enanthate therapy effectively improves libido, erectile function, muscle mass, bone density, mood, energy levels, and overall quality of life in individuals with testosterone deficiency.
Men's testosterone levels naturally decrease with age, this condition is referred to as andropause or late-onset hypogonadism. Usually starting around the age of 30, this deterioration steadily gets worse over time. By the age of 40 or 50, many men may experience symptoms of low testosterone, such as reduced libido, fatigue, decreased muscle mass, and mood changes. Thus, the growing elderly population worldwide is driving the growth of the market.
Additionally, as healthcare expenditure rises, more individuals gain access to healthcare services, including preventive care, diagnostic testing, and specialized treatments. This expanded access enables more men to seek medical advice and treatment for conditions such as hypogonadism, leading to increased demand for TRT. With greater healthcare spending, there is increased investment in diagnostic technologies, screening programs, and healthcare infrastructure. In conclusion, the rising expenditure in the healthcare sector is driving the growth of the market.
However, TRT can be expensive, particularly for long-term treatment. The cost of TRT includes not only the price of testosterone medications but also expenses related to doctor visits, laboratory tests, monitoring, and follow-up appointments. The substantial expense of TRT may present a major obstacle to access for those lacking sufficient health insurance or financial means, restricting their capacity to begin or continue therapy. In conclusion, the high cost of testosterone replacement therapy is hindering the growth of the market.
The market relies on a complex global supply chain for raw materials, manufacturing, and distribution. Disruptions in the supply chain, including factory closures, transportation restrictions, and labor shortages, led to delays in product manufacturing and shortages of TRT medications in some regions. Thus, the COVID-19 pandemic had a negative impact on the growth of the market.
By End User Analysis
By end user, the market is divided into hospital and clinics. The clinics segment attained 66.6% revenue share in the market in 2023. Clinics offer convenient access to healthcare services for individuals seeking diagnosis and treatment for hormone-related conditions such as hypogonadism. Also, clinics are often located in community settings and urban areas, making them easily accessible to patients who may not have access to hospital-based care.
By Product Type Analysis
Based on product type, the market is divided into injectables, topical, and others. The topical segment attained a 19.7% revenue share in the market in 2023. Topical testosterone formulations, such as gels and creams, offer patients more convenience and ease of use than injectable or implantable options. They are typically applied to the skin once daily, allowing for self-administration at home without the need for healthcare provider visits or invasive procedures. This convenience appeals to patients seeking a noninvasive and discreet treatment option for hypogonadism.
By Active Ingredient Analysis
On the basis of active ingredients, the market is segmented into testosterone undecanoate, testosterone cypionate, testosterone, testosterone enanthate, and others. The testosterone cypionate segment recorded 32.65% revenue share in the market in 2023. Testosterone cypionate has a longer half-life and a slower rate of release since it is a long-acting ester of testosterone. This characteristic allows for less frequent dosing, typically every one to two weeks, making it convenient for patients and reducing the burden of frequent injections.
By Regional Analysis
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Europe region generated a 29.18% revenue share in the market in 2023. There is a growing awareness of hypogonadism and testosterone deficiency among healthcare providers and patients in Europe. Healthcare professionals are increasingly proactive in screening for and diagnosing testosterone deficiency, leading to earlier detection and treatment initiation. Additionally, educational campaigns and increased access to information contribute to heightened awareness and demand for TRT among patients.
Recent Strategies Deployed in the Market
Sep-2023: Besins Healthcare Monaco S.A.M. expanded its footprints by inaugurating a novel hormone production facility in Muel, situated near Zaragoza, Spain. Through this expansion, Besins Healthcare strengthened its commitment to expand its production capacity in Europe, boosting it by 30%. Additionally, with expansion, the company aims to meet the demand for hormonal replacement therapies (HRT).
Sep-2022: Marius Pharmaceuticals LLC received approval from the U.S. Food and Drug Administration (FDA) for KYZATREX, an oral testosterone replacement therapy. KYZATREX is used for the treatment of conditions associated with a deficiency or absence of endogenous testosterone in adult males. Additionally, KYZATREX is approved for use in three dosage strengths: 100mg, 150mg, and 200mg.
Mar-2022: Pfizer, Inc. completed the acquisition of Arena Pharmaceuticals, Inc., an American biopharmaceutical company. Through this acquisition, Pfizer gained access to Arena's suite of various treatment candidates developed for gastroenterology, dermatology, and cardiology areas. Additionally, Pfizer received rights to Arena's oral, selective sphingosine 1-phosphate (S1P) receptor modulator, etrasimod, developed for a variety of immuno-inflammatory ailments.
Feb-2022: Eli Lilly and Company signed a clinical trial collaboration and supply agreement with Veru Inc., an oncology biopharmaceutical company. Under this collaboration, the companies would evaluate the efficacy and safety of enobosarm, Veru's oral, chemical entity, selective androgen receptor targeting agonist that activates the androgen receptor (AR), a tumor suppressor, in combination with Lilly's Verzenio (abemaciclib), a CDK4/6 inhibitor, as a second-line therapy in the treatment of AR+ER+HER2-metastatic breast cancer.
List of Key Companies Profiled
Endo International PLC
AbbVie, Inc.
Pfizer, Inc.
Eli Lilly And Company
Teva Pharmaceutical Industries Ltd.
Amneal Pharmaceuticals, Inc.
Ferring Holdings SA
Marius Pharmaceuticals LLC
Besins Healthcare Monaco S.A.M.
Acrux Limited
Global Testosterone Replacement Therapy Market Report Segmentation
By End User
Clinics
Hospital
By Product Type
Injectables
Topical
Others
By Active ingredient
Testosterone Cypionate
Testosterone Undecanoate
Testosterone Enanthate
Testosterone
Others
By Geography
North America
US
Canada
Mexico
Rest of North America
Europe
Germany
UK
France
Russia
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Singapore
Australia
Rest of Asia Pacific
LAMEA
Brazil
Argentina
UAE
Saudi Arabia
South Africa
Nigeria
Rest of LAMEA
Table of Contents
Chapter 1.Market Scope & Methodology
1.1Market Definition
1.2Objectives
1.3Market Scope
1.4Segmentation
1.4.1Global Testosterone Replacement Therapy Market, by End User
1.4.2Global Testosterone Replacement Therapy Market, by Product Type
1.4.3Global Testosterone Replacement Therapy Market, by Active ingredient
1.4.4Global Testosterone Replacement Therapy Market, by Geography
1.5Methodology for the research
Chapter 2.Market at a Glance
2.1Key Highlights
Chapter 3.Market Overview
3.1Introduction
3.1.1Overview
3.1.1.1Market Composition and Scenario
3.2Key Factors Impacting the Market
3.2.1Market Drivers
3.2.2Market Restraints
3.2.3Market Opportunities
3.2.4Market Challenges
3.3Porter's Five Forces Analysis
Chapter 4.Global Testosterone Replacement Therapy Market by End User
4.1Global Clinics Market by Region
4.2Global Hospital Market by Region
Chapter 5.Global Testosterone Replacement Therapy Market by Product Type
5.1Global Injectables Market by Region
5.2Global Topical Market by Region
5.3Global Others Market by Region
Chapter 6.Global Testosterone Replacement Therapy Market by Active ingredients
6.1Global Testosterone Cypionate Market by Region
6.2Global Testosterone Undecanoate Market by Region
6.3Global Testosterone Enanthate Market by Region
6.4Global Testosterone Market by Region
6.5Global Others Market by Region
Chapter 7.Global Testosterone Replacement Therapy Market by Region
7.1North America Testosterone Replacement Therapy Market
7.1.1North America Testosterone Replacement Therapy Market by End User
7.1.1.1North America Clinics Market by Region
7.1.1.2North America Hospital Market by Region
7.1.2North America Testosterone Replacement Therapy Market by Product Type
7.1.2.1North America Injectables Market by Country
7.1.2.2North America Topical Market by Country
7.1.2.3North America Others Market by Country
7.1.3North America Testosterone Replacement Therapy Market by Active ingredients
7.1.3.1North America Testosterone Cypionate Market by Country
7.1.3.2North America Testosterone Undecanoate Market by Country
7.1.3.3North America Testosterone Enanthate Market by Country
7.1.3.4North America Testosterone Market by Country
7.1.3.5North America Others Market by Country
7.1.4North America Testosterone Replacement Therapy Market by Country
7.1.4.1US Testosterone Replacement Therapy Market
7.1.4.1.1US Testosterone Replacement Therapy Market by End User
7.1.4.1.2US Testosterone Replacement Therapy Market by Product Type
7.1.4.1.3US Testosterone Replacement Therapy Market by Active ingredients
